Auriga Laboratories Names Pharmaceutical and Biotechnology Industry Finance Leader as New CFO
The pharmaceutical industry veteran will advance Auriga Laboratories financial and operational processes.
Norcross, GA (PRWEB) October 27, 2005 -- Auriga Laboratories, Inc., http://www.aurigalabs.com, a leading specialty pharmaceutical company, today announced that the board of directors has named Paul Fisher to serve as the company’s Chief Financial Officer.
Fisher, with more than 20 years of leadership experience in finance and accounting, has a proven record in creating world-class finance organizations in the pharmaceutical and biotechnology industries for companies operating in the United States and internationally. He is known for developing best practice financial processes that support improved regulatory compliance, operational performance, and key business initiatives.
Most recently, Fisher was U.S. Corporate Controller at Celltech Group PLC, a leading multinational European biotechnology company listed in the United Kingdom and on the New York Stock Exchange. He was responsible for managing the financial services and reporting for Celltech’s $350 million U.S. commercial, manufacturing, and product development organization, including supporting the filings with the London Stock Exchange and Securities & Exchange Commission, and compliance requirements on behalf of the company’s Audit Committee. During 2004, Celltech Group was acquired for $2.7 billion by UCB, a Belgium pharmaceutical company.
Prior to serving in that role, Mr. Fisher was controller for Medeva UK Pharma Ltd., a pharmaceutical company based in London where he was responsible for the full financial analysis and accounting of the U.K. operating subsidiaries (later acquired by Celltech Group). Earlier in his career, Mr. Fisher held a series of accounting and finance positions in Exxon’s international operations.
Mr. Fisher is certified as a U.K. Qualified Accountant – Chartered Management Accountant, the equivalent of the Certified Public Accountant designation in the United States.
About Auriga
Auriga Laboratories, Inc., develops and markets new prescription products for approved drugs using proprietary drug delivery technologies and reformulation strategies. The specialty pharmaceutical company is based in Norcross, Georgia. A highly integrated team of experienced pharmaceutical industry executives manages product life cycle from development through marketing and sales. The company currently markets Extendryl®, a prescription cough/cold medication, and Trycet™, used to manage pain. More information is available at the company's website at: http://www.aurigalabs.com.
# # #
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
